SCHEMBL5068482

SCHEMBL5068482

COC(=O)c1ccc(CCCOS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD10 O75832 1/20 0.65
KMT2A Q03164 2/20 0.54
CYP4A11 Q02928 2/20 0.54
CYP4F2 P78329 1/20 0.52
TDP1 Q9NUW8 1/20 0.51
MAPT P10636 3/20 0.47
STAT3 P40763 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
ENPP1 P22413 1/20 0.46
GAA P10253 2/20 0.45
CYP2C9 P11712 2/20 0.44
ALDH1A1 P00352 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9252362 0.87 PSMD10 (0.50) PSMD10KMT2AMAPTSTAT3ENPP1
SCHEMBL18934371 0.86 ALDH1A1 (0.47) PSMD10KMT2ACA12CA1CA2
SCHEMBL2567795 0.86 ALDH1A1 (0.47) PSMD10KMT2ACA12CA1CA2
SCHEMBL29768658 0.85 PSMD10 (0.59) PSMD10KMT2ATDP1MAPTSTAT3
SCHEMBL3685139 0.85 PSMD10 (0.48) PSMD10KMT2AGAAALDH1A1LMNA
SCHEMBL5870583 0.84 KMT2A (0.62) PSMD10KMT2ATDP1MAPTSTAT3
SCHEMBL29768597 0.84 PSMD10 (0.58) PSMD10KMT2ATDP1MAPTSTAT3
SCHEMBL9253387 0.83 PSMD10 (0.47) PSMD10KMT2AMAPTSTAT3ENPP1
SCHEMBL18926560 0.82 GAA (0.50) PSMD10KMT2AMAPTCA12CA1
SCHEMBL22084667 0.82 PSMD10 (0.47) PSMD10KMT2ACYP4A11CYP4F2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025262297-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 WO disclosed
US-7384952-B2 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-10 US disclosed
EP-1857459-A2 Pyrazolopyrimidine compound and a process for preparing the same TANABE SEIYAKU CO., LTD. (JP) 2007-11-21 EP disclosed
US-20060135525-A1 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-06-22 US disclosed
EP-1585481-A2 PYRAZOLOPYRIMIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2005-10-19 EP disclosed
WO-2004064721-A2 A PYRAZOLOPYRIMIDINE COMPOUND AND A PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2004-08-05 WO disclosed
US-4906667-A Phenyl hydroxamic acids including a hetero-containing substituent E. R. SQUIBB & SONS, INC. (US) 1990-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135525-A1 Pyrazolopyrimidine compound and a process for preparing the same KCNJ2, KCNN2, KCNH2 PSMD10 1223/4885KMT2A 638/4885CYP4A11 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.